利索-全球专利检索

  1. 登录
  2. 注册
发明公开
CN106236752A 联合用药抗肿瘤药物、制备方法及应用 无效 - 驳回

联合用药抗肿瘤药物、制备方法及应用
摘要：
本发明公开了一种联合用药抗肿瘤药物，包括抗血管生成药物、抗肿瘤细胞增殖药物和两亲性高分子材料；所述抗血管生成药物为康普瑞汀A4的药物前体，所述抗肿瘤细胞增殖药物为喜树碱类抗肿瘤药物。本发明还公开了一种联合用药抗肿瘤药物制剂、制备方法以及应用。细胞毒性实验表明本发明中的纳米粒可以显著抑制肿瘤细胞(HT-29)和人脐静脉血管内皮细胞(HUVEC)的增殖，且有剂量依赖关系；划痕损伤和管腔形成实验也证实本发明中制备的纳米粒能抑制HUVEC的迁移和血管形成。对比单独用药体系，本发明中提供的联合用药纳米粒在体内显示了较好的抑瘤效果，具有良好的临床应用价值和应用前景。
摘要（英）：

The invention discloses a combined antitumor drug. The combined antitumor drug comprises an antiangiogenic drug, a drug used for inhibiting tumor cell proliferation, and an amphiphilic high molecular material; the antiangiogenic drug is a prodrug of Combretastatin A4, and the drug used for inhibiting tumor cell proliferation is a camptothecin antitumor drug. The invention also discloses a combined antitumor drug nanoparticle preparation, a preparation method, and applications. It is shown by cytotoxicity test that the combined antitumor drug nanoparticle preparation is capable of inhibiting proliferation of tumour cell HT-29 and human umbilical vein vascular endothelial cells (HUVEC) obviously, and dose-dependent relationship is detected; it is confirmed by scratch injury experiments and lumen formation experiments that the combined antitumor drug nanoparticle preparation is capable of inhibiting migration of HUVEC and vascularization; compared with single medication systems, the combined antitumor drug nanoparticle preparation possesses excellent tumor killing effect in vivo, clinical application value is high, and application prospect is promising.

0/0